Lunit

328130.KQ

24.30 USD

-1.69

-6.50%

Overview

Last close

24.30 usd

Market cap

737.44M usd

52 week high

58.23 usd

52 week low

22.56 usd

Target price

20.02 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

13.9946

Price/Book Value

7.1699

Enterprise Value

835.70M usd

EV/Revenue

16.3255

EV/EBITDA

-45.3273

Key financials

Revenue TTM

55.49M usd

Gross Profit TTM

-55.46M usd

EBITDA TTM

-47.97M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

277.89M usd

Net debt

43.87M usd

About

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.